they have it posted on yahoo finance--I expected her to say exactly what she said. I am not sure what the viewership for that program is, but I think we just got exposed to 3-4 million potential investors, hence the pop. Data tomorrow would be icing on the cake
yes, that's it, a trade went through for 1000 contracts on the ask--if the stock opens anywhere near the after hours price--they will made some nice $$
sorry, do not follow any of those--because I own this one--I am also keeping my eye on CEMP. If TTPH pays off--I might take a nice position in CEMP--besides the P3 program I look at their ghonnera program--p2 results are outstanding--its got blockbuster written all over it
yea, got that call wrong--I almost bought options today at the low, watch results will come out tomorrow
If primary and secondary endpoints are met--this will more than double the market share of the drug--I am anticipating 60+ on the news alone--anyone else think I'm crazy? with less than 40m shares outstanding:
I would expect partnership would put us in the mid to low 70s or buyout over 100+
I know the ups and downs of the market, but still
The last I spoke with him, he said Fava report being published any day now
stroke trials PH2 were going to startup during summer
phase 2 ALS confirm trial to start during summer, (saw the updated guidance of 2h 2015)
Phase 1 stroke results being published, no date given (still no word)
phase 2 als results being published, but the last PR says they are preparing a final report? so which one is it? will they PR the final conclusion, and then publish it? or wait until its published and then PR it?
and all this was back in March--its now 1.5 weeks away from labor day
come on, seriously
Most of these plans (if you look at the fine print) were established last year or previous years. I think the reason you are seeing increased selling (which again was previously established) was because the company's original guidance was mid year 2015 for the data. Since we are past mid year at this point, most of the plans were setup to have sales go through in August, as the data was supposed to be out by now.
Also keep in mind that they can always give themselves more options at any time. I have seen this over and over again. Believe me, if the data is bad--go point the finger at them, not sure what it will do for you, but at least you could say that they knew the data was bad and they sold all their options. If the data is great, you have no one to blame but yourself for not pulling the trigger to buy more, when now, data is imminent. And when the data comes out, don't be surprised to see management give themselves more shares before the partnership is announced. These guys made a boat load of money with options in the 7 dollar range. Even I would be cashing in some options.
Yes, Heather, we're obviously still finalizing and analyzing the data set. I don't have access to the data you're asking for at this time. Hopefully, we'll have that very soon.
there should be no excuse--there should be data tomorrow--trial was done in June per the last cc--give them a month to lock and analyze the data, then present on 8/5 at the close with the earnings. If not, as once again, during the last call, there will be a lot of questions as to when the data will be presented, given that there is less than 60 days until the end of the Q, I would say the probability is high, that there is data tomorrow PM
I don't think they are recruiting patients anymore--garr said they were done with Phase 1 in Q1 of this year. Phase 2/3 will be more patients at the highest dose level, with the most effectiveness. The results are not out yet because they want to get them published in a peer reviewed journal of some sort. Technically the results could come out any day as it is up to the journal when they get released. They did this because of the reputation of China in general back many years ago. The good news is, is that they sent their own CRO team in there to manage it and gather the data. The doctors (employed by the hospital) were obviously giving the injections into the brain.
Here is the kicker which will move the stock in dollars and not cents:
If the Phase 1 can show any efficacy-like the smith on stocks article talks about, it will be huge--other stem cell companies have tried this (ATHX, ETC...) with no success. i would anticipate a move of 3+ bringing us to the 4-5 range quickly, especially with the shorts.
this is good news, abc stays on top of the story if any progress--same thing happened with NVIV, stock went from 50 cents to 2.5 in a matter of months--any videos